Company: TYRA
Filing Date: 2025-04-18
Form Type: DEF 14A
Source: 0001193125-25-085709
Chunk: 36

Company: Tyra Biosciences, Inc.
Filing Date: 2025-04-18
Form: DEF 14A
Chunk 36
---
 annual performance-based cash bonuses, which were designed to provide appropriate incentives to our executives to achieve defined annual corporate goals and to reward our executives for individual achievement towards these goals. The Compensation Committee has adopted an annual incentive plan (the “Bonus Plan”) under which our employees, including the NEOs, are eligible to receive annual cash bonus payments. The Bonus Plan provides for annual cash bonus opportunities and payouts based on the achievement of specific, pre-establishedcorporate performance objectives and, for certain participants, may be based in part on individual performance. The Compensation Committee will establish the corporate performance objectives each year. An employee’s maximum bonus under the Plan may not exceed 150% of his or her target bonus, unless otherwise determined by the Compensation Committee (or our Chief Executive Officer, for non-executiveemployees). An employee’s target bonus and the weightings between corporate and individual achievement (if any) will be determined by the Compensation Committee (or our Chief Executive Officer, for non-executiveemployees) for each year during the term of the Bonus Plan. At the end of the year, our Compensation Committee will review our performance against each corporate goal and determined the extent to which we achieved each of our corporate goals. For 2024, Dr. Harris’s target bonus was 50% of his then-current base salary, and for each of our other named executive officers, was 40% of their then-current base salary. The corporate goals the Compensation Committee established for 2024 related to clinical milestones and operational development. In February 2025, our Compensation Committee determined that the 2024 goals were achieved at 137% and awarded cash bonuses to each of Dr. Harris, Dr. Warner, and Mr. Bensen based on this assessment in the amount of $433,400, $90,465 and $260,793, respectively. Dr. Warner’s bonus was prorated for the portion of 2024 during which he was employed. Equity-Based Incentive Awards Our equity-based incentive awards are designed to align our interests and those of our stockholders with those of our employees, including our executive officers. The Board or an authorized committee thereof is responsible for approving equity grants. We grant equity awards under the terms of our 2021 Incentive Award Plan (the “2021 Plan”). In August 2024, our Compensation Committee granted options to Dr. Harris and Mr. Bensen to purchase 390,000 shares and 115,000 shares, respectively, of our Common Stock pursuant to the 2021 Plan.